Skip to content

Astra’s Antibody Drug Prevents Covid-19 in High-Risk Groups

  • Cocktail was 77% effective at preventing symptomatic disease
  • U.K. green lights first antibody drug with Regeneron
Updated on

AstraZeneca Plc said its coronavirus antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial, and the U.K. approved a rival’s drug as its first antibody treatment for the disease.

Results from Astra’s study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the virus, the company said in a statement Friday. The trial of 5,197 participants, which started in November, was looking at whether the drug could prevent infection in at-risk groups such as transplant patients and those undergoing chemotherapy.